Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

2017344 citationsReviewhybrid Open Access

Authors

Vibeke Strand · Stanford University

Alejandro Balsa · Hospital Universitario La Paz

Jamal A. Al-Saleh · Dubai Hospital

Leonor Barile-Fabris · Mexican Social Security Institute

Takahiko Horiuchi · Kyushu University Beppu Hospital

Tsutomu Takeuchi · Keio University

Sadiq Lula

Abstract

Based on reviewed reports, biologic/biosimilar immunogenicity differs among agents, with the highest rates observed with infliximab and adalimumab. As ADAb formation in biologic-/biosimilar-treated patients may increase the risk of lost response, the immunogenicity of these agents is an important (albeit not the only) consideration in the treatment decision-making process.

Topics & Keywords

Inflammatory Bowel Disease Systemic Lupus Erythematosus Research Biosimilars and Bioanalytical Methods

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BioDrugs

Volume 31, Issue 4, pp. 299-316

DOI: 10.1007/s40259-017-0231-8

Field-Weighted Citation Impact: 25.76